Migraine is one of the most prevalent and disabling disorders worldwide.1 In addition to triptans, which are used as abortive medications for acute migraine attacks, the US Food and Drug Administration (FDA) has approved several preventive treatments for migraine, including propranolol, topiramate, and onabotulinumtoxinA. Although most of these therapies are relatively inexpensive or available as generics, patients frequently develop symptoms refractory to these agents.2
Hwang TJ, Vokinger KN, Kesselheim AS. New Treatments for Migraine—Therapeutic Ratings and Comparative Coverage in the US, Canada, and Europe. JAMA Intern Med. 2022;182(2):101–102. doi:10.1001/jamainternmed.2021.7168
Artificial Intelligence Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.